REFINEMENT CLINICAL AESTHETICS LTD

Company Registration Number:
16285595 (England and Wales)

Unaudited statutory accounts for the year ended 31 March 2026

Period of accounts

Start date: 2 March 2025

End date: 31 March 2026

REFINEMENT CLINICAL AESTHETICS LTD

Contents of the Financial Statements

for the Period Ended 31 March 2026

Profit and loss
Balance sheet
Additional notes
Balance sheet notes

REFINEMENT CLINICAL AESTHETICS LTD

Profit And Loss Account

for the Period Ended 31 March 2026

13 months to 31 March 2026


£
Turnover: 6,924
Cost of sales: ( 3,027 )
Gross profit(or loss): 3,897
Distribution costs: 0
Administrative expenses: ( 8,402 )
Other operating income: 0
Operating profit(or loss): (4,505)
Interest receivable and similar income: 0
Interest payable and similar charges: 0
Profit(or loss) before tax: (4,505)
Profit(or loss) for the financial year: (4,505)

REFINEMENT CLINICAL AESTHETICS LTD

Balance sheet

As at 31 March 2026

Notes 13 months to 31 March 2026


£
Called up share capital not paid: 2
Current assets
Cash at bank and in hand: 349
Total current assets: 349
Creditors: amounts falling due within one year: 3 ( 4,854 )
Net current assets (liabilities): (4,505)
Total assets less current liabilities: (4,503)
Total net assets (liabilities): (4,503)
Capital and reserves
Called up share capital: 2
Profit and loss account: (4,505 )
Total Shareholders' funds: ( 4,503 )

The notes form part of these financial statements

REFINEMENT CLINICAL AESTHETICS LTD

Balance sheet statements

For the year ending 31 March 2026 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 22 May 2026
and signed on behalf of the board by:

Name: Adam Worthington
Status: Director

The notes form part of these financial statements

REFINEMENT CLINICAL AESTHETICS LTD

Notes to the Financial Statements

for the Period Ended 31 March 2026

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Financial Reporting Standard 101

REFINEMENT CLINICAL AESTHETICS LTD

Notes to the Financial Statements

for the Period Ended 31 March 2026

  • 2. Employees

    13 months to 31 March 2026
    Average number of employees during the period 0

REFINEMENT CLINICAL AESTHETICS LTD

Notes to the Financial Statements

for the Period Ended 31 March 2026

3. Creditors: amounts falling due within one year note

13 months to 31 March 2026
£
Bank loans and overdrafts 0
Amounts due under finance leases and hire purchase contracts 0
Trade creditors 0
Taxation and social security 0
Accruals and deferred income 0
Other creditors 4,854
Total 4,854